L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency.
Twelve subjects suffering from type A chronic respiratory insufficiency were admitted to a double blind, randomized, placebo-controlled trial. The aim of the trial was the evaluation of the effects of the oral administration of L-carnitine, 2 g twice daily for 15 days, on the metabolic and respiratory parameters, at the mild physical work load involved in rehabilitative respiratory physiokinesitherapy. As previously reported, treatment with L-carnitine prevents the metabolic acidosis and hyperventilation caused by physiokinesitherapy in patients with chronic respiratory insufficiency. In correlation with the metabolic role of L-carnitine, the results of this trial suggest that L-carnitine is an essential training-like metabolic factor, particularly when the physical performance is impaired by inadequate respiratory function.
D001784:Blood Gas Analysis; D002331:Carnitine / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D012131:Respiratory Insufficiency / Q000378:metabolism* / Q000628:therapy; D012138:Respiratory Therapy; D014691:Ventilation
D002331:Carnitine